Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biotech Companies Plan Job Reductions

April 14, 2008 | A version of this story appeared in Volume 86, Issue 15

Neurogen has received $30.6 million from private investors that it says will allow it to advance clinical development programs in insomnia, anxiety, restless legs syndrome, and Parkinson's disease. The company had revealed last month that its auditors had doubts about its continued survival. At the same time, the Branford, Conn., company is cutting its workforce by about 45 people in research and administration. In February, it announced the elimination of about 70 employees. Neurogen employed 149 people at the end of 2007. Separately, Keryx Biopharmaceuticals is cutting its workforce in half to about 25 employees. The New York City-based company recently received a negative outcome in a Phase III clinical trial of Sulonex for the treatment of diabetic nephropathy.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.